2005 business performances varied in foreign drug corporations.

The business performance in 2005 by most of foreign multinational drug corporations showed that some company made remarkable sales while net incomes substantially setback.

Pfizer Korea having kept the top rank for several years reported 0.93% of sales down in 2005 at 255,300 MW (5..4% in 2004) and Handok also less sold by 2.9% down from the previous year at 234,400 MW (8.4% in 2004) ...